A clinical update on chronic lymphocytic leukemia. I. Diagnosis and prognosis

Ayalew Tefferi, R. L. Phyliky

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

B-cell chronic lymphocytic leukemia (B-CLL) is a relatively indolent hematologic malignant disease that, despite a good response to nonaggressive orally administered chemotherapy, currently remains incurable. The overall median duration of survival is more than 5 years, and the presence of anemia or thrombocytopenia adversely affects prognosis. B-CLL is readily diagnosed because of the characteristic and specific phenotypic expressions of the neoplastic cells. Clinical staging continues to be the best prognostic indicator in B-CLL. In addition, cytogenetic status, pattern of leukemic infiltration in the bone marrow, and lymphocyte doubling time are now considered to have additional prognostic value. In this article, the diagnostic evaluation of lymphocytosis is discussed, and an updated analysis on the prognostic determinants of B-CLL is provided. The second part of this clinical update, which reviews current chemotherapeutic modalities, will be published in the subsequent issue of this journal.

Original languageEnglish (US)
Pages (from-to)349-353
Number of pages5
JournalMayo Clinic Proceedings
Volume67
Issue number4
StatePublished - 1992

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Leukemic Infiltration
Lymphocytosis
Hematologic Diseases
Cytogenetics
Thrombocytopenia
Anemia
Bone Marrow
Lymphocytes
Drug Therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A clinical update on chronic lymphocytic leukemia. I. Diagnosis and prognosis. / Tefferi, Ayalew; Phyliky, R. L.

In: Mayo Clinic Proceedings, Vol. 67, No. 4, 1992, p. 349-353.

Research output: Contribution to journalArticle

@article{705c36db1bb24d5abf5bafbde1c0ae68,
title = "A clinical update on chronic lymphocytic leukemia. I. Diagnosis and prognosis",
abstract = "B-cell chronic lymphocytic leukemia (B-CLL) is a relatively indolent hematologic malignant disease that, despite a good response to nonaggressive orally administered chemotherapy, currently remains incurable. The overall median duration of survival is more than 5 years, and the presence of anemia or thrombocytopenia adversely affects prognosis. B-CLL is readily diagnosed because of the characteristic and specific phenotypic expressions of the neoplastic cells. Clinical staging continues to be the best prognostic indicator in B-CLL. In addition, cytogenetic status, pattern of leukemic infiltration in the bone marrow, and lymphocyte doubling time are now considered to have additional prognostic value. In this article, the diagnostic evaluation of lymphocytosis is discussed, and an updated analysis on the prognostic determinants of B-CLL is provided. The second part of this clinical update, which reviews current chemotherapeutic modalities, will be published in the subsequent issue of this journal.",
author = "Ayalew Tefferi and Phyliky, {R. L.}",
year = "1992",
language = "English (US)",
volume = "67",
pages = "349--353",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "4",

}

TY - JOUR

T1 - A clinical update on chronic lymphocytic leukemia. I. Diagnosis and prognosis

AU - Tefferi, Ayalew

AU - Phyliky, R. L.

PY - 1992

Y1 - 1992

N2 - B-cell chronic lymphocytic leukemia (B-CLL) is a relatively indolent hematologic malignant disease that, despite a good response to nonaggressive orally administered chemotherapy, currently remains incurable. The overall median duration of survival is more than 5 years, and the presence of anemia or thrombocytopenia adversely affects prognosis. B-CLL is readily diagnosed because of the characteristic and specific phenotypic expressions of the neoplastic cells. Clinical staging continues to be the best prognostic indicator in B-CLL. In addition, cytogenetic status, pattern of leukemic infiltration in the bone marrow, and lymphocyte doubling time are now considered to have additional prognostic value. In this article, the diagnostic evaluation of lymphocytosis is discussed, and an updated analysis on the prognostic determinants of B-CLL is provided. The second part of this clinical update, which reviews current chemotherapeutic modalities, will be published in the subsequent issue of this journal.

AB - B-cell chronic lymphocytic leukemia (B-CLL) is a relatively indolent hematologic malignant disease that, despite a good response to nonaggressive orally administered chemotherapy, currently remains incurable. The overall median duration of survival is more than 5 years, and the presence of anemia or thrombocytopenia adversely affects prognosis. B-CLL is readily diagnosed because of the characteristic and specific phenotypic expressions of the neoplastic cells. Clinical staging continues to be the best prognostic indicator in B-CLL. In addition, cytogenetic status, pattern of leukemic infiltration in the bone marrow, and lymphocyte doubling time are now considered to have additional prognostic value. In this article, the diagnostic evaluation of lymphocytosis is discussed, and an updated analysis on the prognostic determinants of B-CLL is provided. The second part of this clinical update, which reviews current chemotherapeutic modalities, will be published in the subsequent issue of this journal.

UR - http://www.scopus.com/inward/record.url?scp=0026506295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026506295&partnerID=8YFLogxK

M3 - Article

C2 - 1548950

AN - SCOPUS:0026506295

VL - 67

SP - 349

EP - 353

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 4

ER -